Abstract
The finding that cyclooxygenase-2 (COX-2) is over-expressed and plays an important role in carcinogenesis in gastrointestinal (GI) cancers including esophagus, gastric and colorectal cancers has triggered the researches of COX-2 inhibitors as the chemopreventive option for GI cancers. This reviewer updates the current molecular biology on the regulation of COX-2 expression, pharmacological concepts of COX-2 inhibitors in the chemoprevention of GI tract, the clinical efficacies of COX -2 inhibitors in prevention of cancers in GI tract and associated main adverse events. In inflammation, COX-2 expression is regulated both at the transcriptional and posttranscriptional levels. Hypermethylation of the CpG island in the COX-2 gene is the major cause of COX-2 silencing in a subset of GI cancers. However, the tumor-inhibitory efficacy of non-selective non-steroidal antiinflammatory drugs (NSAIDs) or selective COX-2 inhibitors is not necessarily related to their COX-inhibitory potential. These compounds harbor additional pharmacological activities that are entirely independent of its COX-2 inhibitory activity. The clearly identified targets relevant for anticancer therapy, the benefits from clinical chemoprevention of GI tract cancers and the absence of adverse findings of cardiovascular function or histopathology in preclinical toxicology studies indicate the promising results of COX-2 inhibitors. The efficacy and toxicity of NSAIDs are a consequence of the inhibition of the COX enzymes. Therefore, an optimal regime of COX-2 inhibitors in chemoprevention of GI cancers should be further investigated probably by adjustment of dosage, duration, integration of co-therapy and careful selection of candidates.
Keywords: Cyclooxygenase 2, esophagus cancer, gastric cancer, colorectal cancer, Cyclooxygenase 2 inhibitor, aspirin, celecoxib, rofecoxib, carcinogenesis, dosage
Current Pharmaceutical Design
Title:Chemoprevention of Cancers in Gastrointestinal Tract with Cyclooxygenase 2 Inhibitors
Volume: 19 Issue: 1
Author(s): Rui Wang, Linjie Guo, Pu Wang, Wenjuan Yang, Yaoyao Lu, Zhiyin Huang and Chengwei Tang
Affiliation:
Keywords: Cyclooxygenase 2, esophagus cancer, gastric cancer, colorectal cancer, Cyclooxygenase 2 inhibitor, aspirin, celecoxib, rofecoxib, carcinogenesis, dosage
Abstract: The finding that cyclooxygenase-2 (COX-2) is over-expressed and plays an important role in carcinogenesis in gastrointestinal (GI) cancers including esophagus, gastric and colorectal cancers has triggered the researches of COX-2 inhibitors as the chemopreventive option for GI cancers. This reviewer updates the current molecular biology on the regulation of COX-2 expression, pharmacological concepts of COX-2 inhibitors in the chemoprevention of GI tract, the clinical efficacies of COX -2 inhibitors in prevention of cancers in GI tract and associated main adverse events. In inflammation, COX-2 expression is regulated both at the transcriptional and posttranscriptional levels. Hypermethylation of the CpG island in the COX-2 gene is the major cause of COX-2 silencing in a subset of GI cancers. However, the tumor-inhibitory efficacy of non-selective non-steroidal antiinflammatory drugs (NSAIDs) or selective COX-2 inhibitors is not necessarily related to their COX-inhibitory potential. These compounds harbor additional pharmacological activities that are entirely independent of its COX-2 inhibitory activity. The clearly identified targets relevant for anticancer therapy, the benefits from clinical chemoprevention of GI tract cancers and the absence of adverse findings of cardiovascular function or histopathology in preclinical toxicology studies indicate the promising results of COX-2 inhibitors. The efficacy and toxicity of NSAIDs are a consequence of the inhibition of the COX enzymes. Therefore, an optimal regime of COX-2 inhibitors in chemoprevention of GI cancers should be further investigated probably by adjustment of dosage, duration, integration of co-therapy and careful selection of candidates.
Export Options
About this article
Cite this article as:
Wang Rui, Guo Linjie, Wang Pu, Yang Wenjuan, Lu Yaoyao, Huang Zhiyin and Tang Chengwei, Chemoprevention of Cancers in Gastrointestinal Tract with Cyclooxygenase 2 Inhibitors, Current Pharmaceutical Design 2013; 19 (1) . https://dx.doi.org/10.2174/1381612811306010115
DOI https://dx.doi.org/10.2174/1381612811306010115 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Attacking c-Myc: Targeted and Combined Therapies for Cancer
Current Pharmaceutical Design Reversal of ABC Drug Transporter-Mediated Multidrug Resistance in Cancer Cells: Evaluation of Current Strategies
Current Molecular Pharmacology Role of Copper in Angiogenesis and Its Medicinal Implications
Current Medicinal Chemistry Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Novel and Emerging Targeted Therapies of Colorectal Cancer
Current Clinical Pharmacology FAK and WNT Signaling: The Meeting of Two Pathways in Cancer and Development
Anti-Cancer Agents in Medicinal Chemistry Gastrointestinal Stromal Tumors: A Paradigm for Therapeutic Options in Solid Organ Tumors
Mini-Reviews in Medicinal Chemistry Anticancer Properties of the IL-12 Family - Focus on Colorectal Cancer
Current Medicinal Chemistry Epothilones: A Novel Class of Non-taxane Microtubule-stabilizing Agents
Current Pharmaceutical Design Opioid Free Anaesthesia and Cancer
Current Pharmaceutical Design Development of Small-Molecule Inhibitors of Raf
Recent Patents on Anti-Infective Drug Discovery Role of ncRNAs in Development, Diagnosis and Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery Design, Synthesis, and Biological Evaluation of Novel Thiazolyl Substituted Bis-pyrazole Oxime Derivatives with Potent Antitumor Activities by Selectively Inducing Apoptosis and ROS in Cancer Cells
Medicinal Chemistry Angiogenesis Inhibitors. Drug Selectivity and Target Specificity
Current Pharmaceutical Design LncRNA HOTAIR as Prognostic Circulating Marker and Potential Therapeutic Target in Patients with Tumor Diseases
Current Drug Targets Oncogenic Signaling Pathways Activated by RON Receptor Tyrosine Kinase
Current Cancer Drug Targets Gene-Nutrient Interactions in One-Carbon Metabolism
Current Drug Metabolism The GABAergic System and the Gastrointestinal Physiopathology
Current Pharmaceutical Design Effects of Agaricus Blazei Extract Plus Lactoferrin or Lactoferrin Alone on Tumor Growth and UFT-Induced Adverse Reactions in Sarcoma 180- or Highly Metastatic Osteosarcoma LM8-Bearing Mice
The Natural Products Journal The Role of TGF-β Signaling Regulatory MicroRNAs in the Pathogenesis of Colorectal Cancer
Current Pharmaceutical Design